FDA Greenlights Pfizer's Breakthrough Blood Cancer Treatment
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Pfizer's therapy, Elrexfio, for the treatment of difficult-to-treat multiple myeloma, a type of blood cancer. Elrexfio is a bispecific antibody therapy that helps the immune system kill cancer cells. Pfizer estimates the therapy could generate over $4 billion in peak revenue. The FDA approval is based on positive results from a mid-stage study, and Pfizer will continue testing the therapy in late-stage trials. Other similar antibody therapies in the market include Roche's Columvi, Abbvie's Epkinly, and Johnson & Johnson's Talvey.